Cancer drug interaction study tests antifungal and antibiotic effects

NCT ID NCT05338489

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how two common drugs—itraconazole (an antifungal) and rifampin (an antibiotic)—change the way the body processes selpercatinib, a cancer medication. Twenty-four healthy adults took selpercatinib alone and then with each of the other drugs. Researchers measured drug levels in the blood to see if doses need adjustment. The goal is to ensure safe and effective use when these drugs are combined in cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selpercatinib (also called LOXO-292), itraconazole, and rifampin
What this could lead to: If successful, this study will help doctors understand how to adjust selpercatinib doses when patients take common antifungal or antibiotic drugs, making treatment safer.
What could go wrong: This is an early-stage study in healthy volunteers, not patients. The results may not fully predict effects in people with cancer or those taking other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Celerion

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.